Abstract |
The aim of the present study was to find out whether (+/-)-8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), a prototypical 5-HT1A agonist, and (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane HCl (EMD 128130), a compound with serotonin 5-HT1A-agonist and dopamine D2-like antagonist properties, are able to attenuate the haloperidol-induced (1 mg/kg) muscle rigidity in rats. Muscle tone was examined using a combined mechano- and electromyographic (EMG) method that simultaneously measured the mechanical muscle resistance (MMG) of the rat's hind foot to passive movements in the ankle joint, and the EMG activity of two antagonist muscles. Both 8-OH-DPAT (0.125-0.5 mg/kg i.p.) and EMD 128130 (1-10 mg/kg i.p.) dose-dependently decreased the haloperidol-enhanced MMG to passive movements, as well as the tonic and the long-latency reflex EMG activities. Provided these results can be extrapolated to humans, the efficacy of EMD 128130 in relieving the haloperidol-induced muscle rigidity supports the concept that novel antipsychotics with 5-HT1A agonist and dopamine D2 antagonist activities should have a favourable extrapyramidal side-effect profile.
|
Authors | E Lorenc-Koci, J Wardas, G D Bartoszyk, S Wolfarth |
Journal | Neuropharmacology
(Neuropharmacology)
Vol. 45
Issue 8
Pg. 1057-69
(Dec 2003)
ISSN: 0028-3908 [Print] England |
PMID | 14614949
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antiparkinson Agents
- Organic Chemicals
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Receptor, Serotonin, 5-HT1A
- sarizotan
- 8-Hydroxy-2-(di-n-propylamino)tetralin
- Haloperidol
|
Topics |
- 8-Hydroxy-2-(di-n-propylamino)tetralin
(pharmacology)
- Animals
- Antiparkinson Agents
(pharmacology)
- Haloperidol
(toxicity)
- Male
- Muscle Rigidity
(chemically induced, physiopathology)
- Organic Chemicals
- Rats
- Rats, Wistar
- Receptor, Serotonin, 5-HT1A
(physiology)
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
(pharmacology)
|